[Podcast] The Power of Persistence: From Biotech Incubator to Product Launch

#back-to-top { display: block; position: fixed; bottom: 0rem; left: 0rem; z-index: 9999; width: 100%; height: 40px; text-align: center; line-height: 40px; background: #000; color: #fff; cursor: pointer; border: 0; border-radius: 2px; text-decoration: none; transition: opacity 0.2s ease-out; opacity: 0;} #back-to-top:hover { background: #333;} #back-to-top.show { opacity: 1;} @media only screen and (min-width: 40rem) { #back-to-top { background: #d62828; height: 40px; line-height: 40px; bottom: 0.75rem; left: 0.75rem; width: 40px; }} @media only screen and (min-width: 70rem) { #back-to-top { height: 50px; line-height: 50px; bottom: 1rem; left: 1rem; width: 50px; }} .timeline .figure_content { padding-top: 1rem;} .timeline h2 { font-size: 1.625rem; font-weight: 800; margin: 0 0 1rem 0;} .timeline h2 a { text-decoration: none;} .timeline h2 a:hover { text-decoration: underline;} .timeline ol { -webkit-columns: 1; -moz-columns: 1; columns: 1; list-style: none; margin: 1rem 0 0 0; position: relative;} .timeline ol li { font-weight: 700; margin: 0 0 0.75rem 1rem; position: relative;} .timeline ol li .list-date { display: inline-block; font-size: 0.875rem; font-weight: 400; padding-right: 0.5rem; width: 40px;} .timeline ol li a { font-size: 1rem; font-weight: 700; text-decoration: none;} .timeline ol li a:hover { text-decoration: underline;} .timeline ol li:before { background-color: #000; border-radius: 50%; content: ””; height: 10px; left: -20px; position: absolute; top: 5px; width: 10px;} .timeline ol li:after { position: absolute; content: ''; display: inline-block; background-color: #000; width: 2px; left: -16px; top: 15px; height: 110%;} .timeline ol li:last-of-type:after { display: none;} .timeline .brief-item { margin-top: 3rem; position: relative;} .timeline .brief-item:last-of-type:after { height: 100%;} .timeline .brief-item .brief-item-img { margin: 0.5rem 0 0 0;} .timeline .brief-item .details { margin: 0;} .timeline .brief-item .image-cite { color: #999; font-size: 0.875rem;} .timeline .brief-item .image-cite .credit { font-style: italic;} .timeline .brief-item .image-cite .credit a { color: #999;} .timeline .brief-item .date-tag { background-color: #000; color: #fff; display: inline-block; font-weight: 800; font-size: 0.875rem; line-height: 20px; margin: 0.25rem 0; padding: 0.25rem 0.5rem;} .timeline .last-updated { color: #d62828; font-style: normal; font-size: 1rem; font-weight: 700;} .timeline .learn-more { font-style: italic; margin-top: 2rem; font-size: 1rem;} @media only screen and (min-width: 40rem) { /* Change to 1 if column needs to be larger */ .timeline ol { -webkit-columns: 1; -moz-columns: 1; columns: 1; } .timeline ol li { margin-left: 0; } .timeline ol li:before, .timeline ol li:after { display: none; } .timeline h2 { margin: 0 0 1rem 0; font-size: 2rem; } .timeline .brief-item .brief-item-img { margin: 1.5rem 0 0 0; } .timeline .brief-item:before { background-color: #000; border-radius: 50%; content: ””; height: 15px; left: -40px; position: absolute; top: 5px; width: 15px; } .timeline .brief-item:after { position: absolute; content: ''; display: inline-block; background-color: #000; width: 2px; left: -33px; top: 15px; height: 102%; } .timeline .brief-item .date-tag { margin: 0 0 1rem 0; } .timeline .brief-item .date-tag:before { content: ””; position: absolute; left: -14px; top: 0; width: 0; height: 0; border-top: 14px solid transparent; border-bottom: 14px solid transparent; border-right: 14px solid #000; }}
Welcome to ”The Power of Persistence: From Biotech Incubator to First Product Launch,” a three-episode podcast series featuring seasoned experts who share valuable insights and tips about bringing biotech products to market. In this series, we delve into the journey of BioLineRx, a biopharmaceutical company founded in Israel, from its inception as a biotech incubator to achieving FDA approval for its first product, motixafortide.
Check out the podcast episode below.
Ep. 1 From Incubation to Laser-Focused Biotech Innovation
Ep. 1
From Incubation to Laser-Focused Biotech Innovation In the inaugural episode, we explore the origins of BioLineRx and its transformation from a biotech incubator to a fully-fledged biotech company. Joined by Phil Serlin, CEO of BioLineRx, we uncover the company's early days, its broad pipeline spanning various therapeutic areas, and the strategic decision-making process that led to its evolution. From strategic evaluations to pivoting towards oncology and hematology, this episode highlights the importance of persistence and strategic adaptability in the biotech industry.
Listen to ”From Incubation to Laser-Focused Biotech Innovation” on Spreaker. //smooth scroll $(function() { $('a[href*=”#”]:not([href=”#”])').click(function() { if (location.pathname.replace(/^//,'') == this.pathname.replace(/^//,'') && location.hostname == this.hostname) { var target = $(this.hash); target = target.length ? target : $('[name=' + this.hash.slice(1) +']'); if (target.length) { $('html, body').animate({ scrollTop: (target.offset().top - 100) }, 1000); return false; } } }); }); if ($('#back-to-top').length) { var scrollTrigger = 1400, // px backToTop = function () { var scrollTop = $(window).scrollTop(); if (scrollTop > scrollTrigger) { $('#back-to-top').addClass('show'); } else { $('#back-to-top').removeClass('show'); } }; backToTop(); $(window).on('scroll', function () { backToTop(); });}
post
share
post
print
email
Filed Under: Pharma, Clinical Trials '
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.